We describe a molecular analysis of 184 cystic fibrosis (CF) families in Wales. To determine accurate frequency data for the CF mutations in the Welsh population, families with at least three Welsh grandparents were strictly regarded as Welsh. Of these 74 families, we have identified approximately 90% of mutations causing CF, with AF508 accounting for 71P8% and 621 + 1G > T 6-7%. We observed a significant difference between the Welsh and Scottish frequencies of 621 + IG > T.
71P8% and 621 + 1G > T 6-7%. We observed a significant difference between the Welsh and Scottish frequencies of 621 + IG > T.
To allow the rapid and efficient screening for the more common mutations we modified a multiplex used by Watson et a) enabling the detection of AF508, G551D, and R553X simultaneously with 621 + IG > T. In parallel to this system we ran the Cellmark Diagnostics ARMS multiplex kit, which detects AF508, 621 + 1G > T, G551D, and G542X.
RFLP analysis of the 184 families shows that the AF508 chromosomes are almost exclusively found on the B haplotype (XV2c 1, KM19 2); the other CF mutations have more heterogeneous backgrounds. Strong haplotype correlations exist between the markers XV2c, KM19, D9, and G2 and the other CF mutations. Haplotype data suggest that there are at least seven mutations that remain to be identified in these families. (J Med Genet 1992;29: In 1989 the cystic fibrosis transmembrane conductance regulator (CFTR) gene and the most common mutation, AF508, were identified. '`3 Marked variations in the frequency of AF508 have been reported from different populations.4
For example, in different regions of Europe, Figure 1 The ARMS multiplex analysed on a 3% NuSieve gel. Samples I to 3 are normal, 4 is a AF508 heterozygote, 5 a G542X/AF508, 6 a G551D/AF508, 7 a 621 + I G > T/AF508, and 8 a GSSID homozygote.
AF508 varies from as low as 30% to as high as 80%.5 A large number of other mutations have also been reported in the CFTR gene,6"5 although the majority have been identified only in individual cases. From a study of 184 cystic fibrosis families referred to our centre, we have established the frequency of the AF508 mutation and many of the rarer mutations in the Welsh population. Additionally we have performed extensive RFLP analysis particularly on the non-AF508 CF chromosomes and established haplotype correlations with the other mutations. From these studies we have predicted the number of mutations that remain unidentified in our total population. J3. 11) was performed on the non-AF508 CF chromosomes.
Materials and methods
The classification of pancreatic insufficiency (PI) or pancreatic sufficiency (PS) was made depending on whether the patient needed enzyme supplementation or not (all those regarded as PS had a three day faecal fat excretion test). Where there was uncertainty or if it was not possible to make a diagnosis, the patient was classified as P?.
Results
The frequencies of the CF mutations studied to date in the 184 families are presented in table 1. We have identified a total of 89-8% of CF mutations in the Welsh population, with AF508 accounting for 718%, 621+1G>T 6 7%, G542X 2-7%, and R1283M 2-0%. The differences in the numbers of each mutation between the Welsh and the mixed groups were relatively small and not statistically significant. To ensure that the mixed group was not disguising any significant differences, since it contained some families with one or two Welsh grandparents, for each individual chromosome the probability of it being Welsh was then calculated. When two groups were divided into Welsh and not Welsh (each chromosome could count as partially Welsh and would contribute accordingly to the Welsh total, and vice versa), no significant differences were seen. For subsequent haplotype analysis the data sets were thus pooled.
A comparison of the numbers of each mutation in the Welsh group and the Scottish population'9 was carried out. Expected numbers for each mutation in the different groups were calculated, and the mutations with expected numbers less than 2-5 in the Welsh or Scottish groups were combined into a single category of rare mutations. AF508 was not included in the analysis, as it was already known to have a fairly uniform frequency within the British population.5 Statistical analysis involved a x2 analysis with 4 degrees of freedom (df). Results showed a X2 value of 27 2 which is the equivalent to a p value < < 0 0005. The difference in frequency of 621 + 1G> T was almost solely responsible for these significant findings. When this mutation alone was compared to all others combined, a X2 of 23-8 was obtained (1 df, p < 0-000001). Table 2 shows the distribution of genotypes in the 185 patients in this study. A detailed genotype/phenotype analysis will be published elsewhere (L Al-Jader, personal communication); however, it is interesting to note here that none of the pancreatic sufficient patients are homozygous for AF508. In general we have very few pancreatic sufficient patients in our total population; however, a more detailed examination of our unclassified group may slightly alter this distribution.
From table 3 it can be seen that all but one of the AF508 chromosomes are associated with the B haplotype, the exception being on the D haplotype. The other CF mutations have more heterogeneous backgrounds, although the majority are still associated with the B haplotype, followed by the C haplotype. Normal chromo- Figure 2 The Cardiff multiplex analysed on a 10% polyacrylamide gel. Sample I is normal, 2 a AF508 heterozygote, 3 a AI507 heterozygote, 4 a G551D or R553X heterozygote, and 5 a 621 + I G > T heterozygote. somes carry mainly the A or C haplotypes. Extensive RFLP analysis on the non-AF508 CF chromosomes (table 4) shows that with the markers XV2c, KM19, D9, and G2, strong haplotype associations with the other mutations can be observed. For example 621 + 1 G > T is found exclusively on the 1,2,2,2 haplotype, G55 ID is exclusively on the 1,2,2,1 haplotype, and R1283M is always on the 2,2,2,1 haplotype. R553X, however, is associated with two haplotypes (2,1,1,1 and 1,1,2,2) which is consistent with the hypothesis that this is a recurrent mutation.20
Using this correlation, we have attempted to determine the number of mutations that remain unidentified in our total population. Through classifying the remaining 40 unidentified CF chromosomes according to their XV2c, KM19, G2, and D9 haplotypes, at least seven different groups can be established (table 5) . The chromosomes with incomplete '7 to allow the simultaneous detection of this mutation with AF508, AI507, G551D, and R553X; 82-3% of our total CF chromosomes can thus be screened using this system. In parallel to this we ran the ARMS multiplex which detects AF508, G551D, G542X, and 621 + 1G > T, thus accounting for 83-1 % of our total CF chromosomes. Both systems have proved reliable in our hands and the ARMS multiplex is particularly robust.
The distribution of genotypes in our patients tends to support the observation that AF508 is a severe allele. Kerem et aP suggested that patients homozygous for any combination of the severe alleles will be pancreatic insufficient, and that patients carrying either a single severe allele or two mild alleles will be pancreatic sufficient. G85E has been categorised as a severe allele by Zielenski et al. 6 However, more recently, Chalkley and Harris24 have reported that G85E may be associated with milder disease (that is, a mild allele). In either case, the fact that one of our five AF508/G85E affected subjects is pancreatic sufficient and the other four are insufficient is in conflict with the hypothesis proposed by Kerem et al.3 TaqI  TaqI  TaqI  PstI  MspI  XbaI  MspI  PI  PS  P?   1  2  1  2  2  2  2  9  1  2  1  2  2  2  1  1  1  2  1  2  2  2  -1  -2  1  2  2  2  1  1  1  -1  2  2  2  2  1  1  -1  2  2  2  -1  --1  2  2  2  2  1  1  -1  2  -2  2  --1  2  -2  2  1  1  2  ---2  2  1  17   1  2  1  2  2  1  2  -1  1  2  2  1  2  1  -1  2  2  1  2  1  -1  2  2 Haplotype analysis on disease chromosomes aids the study of the molecular defects of each of the respective mutations. Our data are consistent with the observation that the majority of AF508 chromosomes are characterised by the B haplotype, suggesting a common origin. In fact only one of the AF508 chromosomes is associated with the D haplotype, which may have arisen through a crossover event. 5 The other CF mutations are characterised by a more heterogeneous background of haplotypes.
Strong correlations exist between the markers XV2c, KM19, D9, and G2 and the other mutations. We have categorised the remaining unidentified CF mutations according to their haplotypes with these markers. Since seven distinct haplotype groups exist, we would predict at least seven mutations remain to be characterised in our total population; often more than one mutation exists on a single haplotype5 (this study). Additionally, the inability to set phase in some of the chromosomes potentially lowers the proportion of CF haplotypes, so this estimate will be on the conservative side. However, if recurrent mutations are among those that remain uncharacterised at present (these may be associated with more than one haplotype), then fewer unidentified mutations would be predicted.
We wish to thank Professor P S Harper, Dr D Shaw, and Dr A Clarke for their useful comments on this manuscript, Dr Group I  1  2  2  2  2  2  1  1  Total  0  1  0   Group II   1  2  2  2  2  1   -1  1  -2  2  2  1  -1  Total  1  1  0   Group III   2  1  2  1  1  2  1  3  5  2  1  2  1  1  2  2  3  2  1  2  1  1  2  -1  1  1  2  1  1  2  1  1  2  1  -1  1  2  1  2  2  1  -1  1  2  -2  1  --1  1  2  2  1  ---1  1  2  2  1  -1  -1  1  2  1 
